Drug profile · INN
belumosudil mesylate
REZUROCK
belumosudil mesylate (REZUROCK) is a rho-associated protein kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — belumosudil mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
belumosudil mesylate (REZUROCK) is a rho-associated protein kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Rho-associated protein kinase inhibitor
Primary target: Rho-associated protein kinase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is belumosudil mesylate?
belumosudil mesylate (REZUROCK) is a rho-associated protein kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for belumosudil mesylate?
REZUROCK is a marketed brand name for belumosudil mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of belumosudil mesylate?
belumosudil mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.